US OptionsDetailed Quotes

AZN250411P66000

Watchlist

2.50
0.000.00%

15min DelayClose Apr 11 15:59 ET

0.00High0.00Low

AstraZeneca Stock Discussion

Teddy123

Apr 8 14:41

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca

$AstraZeneca (AZN.US)$
Revolutionary AI Technology Detects Lung Cancer Mutations Without Invasive Testing

Teddy123

Apr 8 14:41

DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

$AstraZeneca (AZN.US)$
New Breast Cancer Drug DATROWAY Shows 37% Better Survival Rates in EU Approval

Movers and Shakers

Apr 3 20:16

Columns Today's Pre-Market Movers and Top Ratings | TSLA, AAPL, AZN and More

Morning Movers
Gapping Up
$Diageo (DEO.US)$ shares rose 4.6% in pre-market trading, as U.S. tariffs avoided the worst-case scenario for spirits. Goodbody noted no new duties on Canadian and Mexican imports, while Jefferies highlighted the avoidance of a potential 200% tariff on EU alcohol, benefiting European distillers.
Pharmaceutical shares are up in pre-market trading as drug imports could be exempt from the new 'reciprocal ta...

Tariff turmoil: How to achieve balance in volatile markets?

Teddy123

Mar 31 19:22

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

$AstraZeneca (AZN.US)$
Breakthrough: First-Ever FDA-Approved Immunotherapy Shows 32% Better Outcomes in Bladder Cancer

Teddy123

Mar 26 12:33

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

$AstraZeneca (AZN.US)$
Major Breakthrough: AstraZeneca's TAGRISSO Extends Lung Cancer Survival to Nearly 5 Years

Teddy123

Feb 28 21:12

$AstraZeneca (AZN.US)$
ENHERTU Shows 38% Reduced Death Risk in Breast Cancer - EU Approval Now One Step Closer

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Teddy123

Feb 26 20:14

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor

$AstraZeneca (AZN.US)$
Can This Breakthrough Breast Cancer Drug Transform AstraZeneca's Oncology Portfolio?

Ryand83

Feb 25 08:28

$LumiraDx (LMDXF.US)$ if we started bringing awareness to X FB and other social media platforms we could probably win this fight. I stayed in Lumiradx because I figured if $AstraZeneca (AZN.US)$ had scooped it up we would have been jipped. $ROCHE HOLDING AG (RHHBY.US)$ seemed like a better fit as they have a plethora of innovative solutions to revitalize companies. 350m seems like an $Abbott Laboratories (ABT.US)$ or $Johnson & Johnson (JNJ.US)$ move to me and I don't buy it. Not from Roche.

Teddy123

Feb 24 17:05

Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing

$Sophia Genetics (SOPH.US)$ $AstraZeneca (AZN.US)$
Global Healthcare Revolution: Elite Hospitals Rush to Implement This Game-Changing Cancer Test

Teddy123

Feb 15 03:14

IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-h

$AstraZeneca (AZN.US)$
Breakthrough in Bladder Cancer Treatment: AstraZeneca's IMFINZI Slashes Disease Progression Risk by 42%

No comment yet